Retatrutide: What the Research Actually Shows

Published by Scandinavian Pen Peptide

Retatrutide is a triple receptor agonist — it targets GLP-1, GIP, and glucagon receptors simultaneously. That’s a meaningful distinction from semaglutide (GLP-1 only) and tirzepatide (GLP-1 and GIP), and the phase 2 clinical data reflects it. Weight reductions of up to 24% over 48 weeks put it ahead of anything currently approved for obesity treatment.

It’s still in clinical development. But for researchers tracking the metabolic peptide space, retatrutide is probably the most interesting compound to follow right now.

For quick background on peptides generally, see our FAQ. To browse available compounds, visit our full range. For broader context on GLP-1 class compounds, see our peptide research guide.

What Retatrutide Is

Retatrutide (LY3437943) is a synthetic peptide developed by Eli Lilly. It binds to three distinct hormone receptors that each play a different role in metabolic regulation:

• GLP-1R — reduces appetite, improves insulin sensitivity, slows gastric emptying.
• GIPR — amplifies post-meal insulin response, influences adipose tissue metabolism.
• GcgR — increases thermogenesis, stimulates hepatic lipolysis, raises basal energy expenditure.

The glucagon component is what sets it apart from tirzepatide. Glucagon receptor activation drives additional fat breakdown and increases energy expenditure at rest — effects that GLP-1 and GIP agonism alone don’t produce. This triple mechanism is why researchers refer to retatrutide as a “triple G” agonist.

How It Compares to Semaglutide and Tirzepatide

The progression here is fairly clear when you look at the clinical numbers:

• Semaglutide (GLP-1 only) — 15–17% average body weight reduction in phase 3 trials. Approved for obesity and type 2 diabetes (Ozempic, Wegovy).
• Tirzepatide (GLP-1 + GIP) — up to 22% weight reduction in phase 3 studies. Also approved (Mounjaro, Zepbound).
• Retatrutide (GLP-1 + GIP + glucagon) — 17.5% to 24.2% weight reduction depending on dose, over 48 weeks, in phase 2 data. Not yet approved.

Each generation adds a receptor mechanism. Whether that translates to meaningfully better outcomes in broader populations — and what the long-term safety profile looks like — is what phase 3 trials are designed to answer. Phase 2 data is promising but not conclusive.

The Clinical Data

The primary source for retatrutide’s human data is a phase 2 study published in the New England Journal of Medicine in 2023. It enrolled obese patients without diabetes and ran for 48 weeks.

Key findings:

• Weight reduction ranged from 17.5% to 24.2% depending on dose — higher doses produced greater reductions, with the curve still trending downward at the end of the study period, suggesting the plateau had not yet been reached.
• Lipid parameters improved significantly. Triglycerides dropped, HDL increased — both favorable cardiovascular markers.
• Hepatic fat was substantially reduced, which has implications for non-alcoholic fatty liver disease (NAFLD/MASH) research — a condition with very limited approved treatment options.
• Fasting glucose and HbA1c also improved, suggesting metabolic effects that extend beyond weight loss alone.
• Lean mass preservation is an open question. GLP-1 class drugs are known to reduce both fat and lean mass; whether retatrutide’s glucagon component changes that ratio is being investigated.

The full study is available on PubMed — search “retatrutide LY3437943” to find it directly.

What Phase 3 Needs to Answer

Phase 2 trials are designed to establish proof of concept and dose range — not to confirm safety and efficacy at scale. The questions that remain for retatrutide include:

• Does the weight loss plateau at a higher or lower level than phase 2 suggests?
• What does the cardiovascular outcomes data look like? (Semaglutide has demonstrated CV benefit; tirzepatide trials are ongoing.)
• Are there safety signals — particularly around bone density, lean mass loss, or thyroid — that didn’t appear in smaller studies?
• How does it perform in patients with type 2 diabetes, where the GIP and glucagon components interact differently with existing insulin resistance?

Phase 3 enrollment is underway. Results are expected in the 2025–2027 timeframe depending on the trial arm.

Side Effects Reported in Clinical Research

The side effect profile looks similar to other GLP-1 class compounds. The most common issues reported in the phase 2 trial were gastrointestinal: nausea, vomiting, diarrhea, and constipation, particularly during dose escalation. Appetite reduction, fatigue, and injection site reactions were also reported.

These effects were generally dose-dependent and most pronounced at the start of treatment — a pattern consistent with semaglutide and tirzepatide. Whether they attenuate over longer treatment periods is part of what phase 3 will clarify. The glucagon component raises additional questions around potential effects on heart rate and blood pressure that warrant monitoring in larger trials.

Retatrutide in the Broader Research Context

Retatrutide sits at the leading edge of a rapidly evolving field. For comparison, semaglutide’s phase 2 data showed approximately 10–12% weight reduction — the phase 2 numbers for retatrutide are substantially higher. That said, the history of metabolic drug development includes compounds that performed well in early trials and less well at scale.

What makes retatrutide scientifically interesting beyond the weight numbers is the NAFLD signal. Non-alcoholic fatty liver disease affects an estimated 25% of the global population and has no approved pharmacological treatment. If the hepatic fat reduction seen in phase 2 holds in larger trials, that’s a meaningful research finding independent of the obesity indication.

For context on related compounds, see our guides on BPC-157 and TB-500, or browse the broader peptide research landscape.

Storage

Store at 2–8°C, away from direct light and moisture. For long-term storage, −20°C is standard. Avoid repeated freeze-thaw cycles — each cycle degrades peptide integrity. Lyophilized powder is more stable than reconstituted solution. All Scandinavian Pen Peptide orders ship in temperature-controlled refrigerated packaging.

⚠️ Research use only. Retatrutide is available from Scandinavian Pen Peptide strictly for scientific research purposes. It is not intended for human use or therapeutic application. For questions about this or other compounds, visit our FAQ or contact us. Interested in distribution? See our distributor page.